Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Nickelsen

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Ugeskrift for Laeger|November 4, 2005
[The Danish Colorectal Cancer Database]Henrik Harling, Thomas Nickelsen
Chronobiology International|October 31, 2002
Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift: results of a placebo-controlled trialThomas Nickelsen, Alexander Samel, Martin Vejvoda, et al.
Current Medical Research and Opinion|October 8, 2008
Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS studyHelmut Minne, Maurice Audran, Maria E Simões, et al.
Maturitas|June 22, 2005
Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1Patrick Neven, Deborah Quail, Fernando Marin, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|March 6, 2003
A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetatePatrick Neven, Tore Lunde, Pierluigi Benedetti-Panici, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 27, 2003
Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trialJean Yves Reginster, Dieter Felsenberg, Imre Pavo, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|August 29, 2002
A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of lifeSimon Voss, Deborah Quail, Alison Dawson, et al.
The Journal of Clinical Endocrinology and Metabolism|December 28, 2007
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosisSteven Boonen, Fernando Marin, Barbara Obermayer-Pietsch, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 29, 2008
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatmentBarbara M Obermayer-Pietsch, Fernando Marin, Eugene V McCloskey, et al.
American Journal of Obstetrics and Gynecology|December 14, 2004
Predictors of hot flushes in postmenopausal women who receive raloxifene therapyJosé M Aldrighi, Deborah C Quail, Jacques Levy-Frebault, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Ugeskrift for Laeger|November 4, 2005
[The Danish Colorectal Cancer Database]Henrik Harling, Thomas Nickelsen
Chronobiology International|October 31, 2002
Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift: results of a placebo-controlled trialThomas Nickelsen, Alexander Samel, Martin Vejvoda, et al.
Current Medical Research and Opinion|October 8, 2008
Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS studyHelmut Minne, Maurice Audran, Maria E Simões, et al.
Maturitas|June 22, 2005
Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1Patrick Neven, Deborah Quail, Fernando Marin, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|March 6, 2003
A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetatePatrick Neven, Tore Lunde, Pierluigi Benedetti-Panici, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 27, 2003
Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trialJean Yves Reginster, Dieter Felsenberg, Imre Pavo, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|August 29, 2002
A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of lifeSimon Voss, Deborah Quail, Alison Dawson, et al.
The Journal of Clinical Endocrinology and Metabolism|December 28, 2007
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosisSteven Boonen, Fernando Marin, Barbara Obermayer-Pietsch, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 29, 2008
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatmentBarbara M Obermayer-Pietsch, Fernando Marin, Eugene V McCloskey, et al.
American Journal of Obstetrics and Gynecology|December 14, 2004
Predictors of hot flushes in postmenopausal women who receive raloxifene therapyJosé M Aldrighi, Deborah C Quail, Jacques Levy-Frebault, et al.
Pageof 2